SCHEMBL217071

SCHEMBL217071

C[C@H](Nc1ncc(F)c(Nc2cc(C3CC3)[nH]n2)n1)c1ncc(F)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 1.00
NTRK1 P04629 11/20 0.78
JAK3 P52333 4/20 0.73
IGF1R P08069 5/20 0.59
AURKA O14965 2/20 0.59
PLK4 O00444 1/20 0.59
STK10 O94804 1/20 0.59
PAK4 O96013 1/20 0.59
RET P07949 1/20 0.59
FGFR1 P11362 1/20 0.59
FER P16591 1/20 0.59
CSNK2A2 P19784 1/20 0.59
JAK1 P23458 1/20 0.59
TYK2 P29597 1/20 0.59
FLT3 P36888 1/20 0.59
STAT3 P40763 1/20 0.59
STAT5A P42229 1/20 0.59
CDK3 Q00526 1/20 0.59
PTK2 Q05397 1/20 0.59
TNK2 Q07912 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL217828 0.90 JAK2 (0.82) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL4903525 0.87 NTRK1 (1.00) JAK2NTRK1JAK3IGF1R
SCHEMBL3347118 0.86 JAK2 (0.75) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL22535810 0.86 JAK2 (0.75) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL217992 0.84 JAK2 (1.00) JAK2NTRK1JAK3AURKAPLK4
SCHEMBL22535278 0.83 JAK2 (0.71) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL22535307 0.83 JAK2 (0.71) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL22535636 0.82 JAK2 (0.69) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL3033143 0.82 NTRK1 (0.75) JAK2NTRK1JAK3IGF1RAURKA
SCHEMBL15208918 0.82 JAK2 (0.69) JAK2NTRK1JAK3IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088784-B2 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer ASTRAZENECA AB (SE) 2012-01-03 US disclosed